Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Finnigan, Paradigm Ink Metabolomics Partnership

NEW YORK, Nov. 6 — A division of Thermo Electron and Paradigm Genetics have formed a partnership to design new technologies for use in metabolomics, also known as the study of the interactions between small molecules, the companies said on Tuesday.

The companies plan to use chromatography and mass spectrometry systems to develop a new way to identify and validate metabolite biomarkers that they believe may be useful in drug discovery. 

Under the terms of the arrangement, Paradigm, of Research Triangle Park, NC, will provide technical consulting services in exchange for exclusive pre-commercial access to new systems made by Thermo Finnigan. Paradigm, which is publicly owned, specializes in functional genomics and metabolic profiling technologies. 

Financial terms of the agreement were not disclosed.

Thermo Finnigan, based in Waltham, Mass., specializes in mass spectrometers, chromatography systems, related software, and multi-instrument combinations of these products. 

The companies did not disclose any further financial details of the agreement.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.